Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
77,650.72
(
0.23%
)
News Focus
News Focus
Post# of 704048
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

madrose1

Send PM Follow Ignore
Followers 282
Posts 47139
Boards Moderated 10
Alias Born 04/07/2001

madrose1

Member Level

Re: madrose1 post# 456504

Monday, 02/13/2006 8:38:32 AM

Monday, February 13, 2006 8:38:32 AM

Post# of 704048

08:31 MYOG Myogen Reports Positive Top Line Results for Ambrisentan LFT Rescue Study In Pulmonary Arterial Hypertension (36.99 )

Co today announced positive top line results of the AMB-222 study, an open-label study of ambrisentan in patients with pulmonary arterial hypertension who have previously discontinued bosentan and/or sitaxsentan treatment due to liver function abnormalities. Based on results to date and the properties of ambrisentan, Myogen believes that, if ambrisentan is ultimately approved, it may offer significant clinical benefit to PAH patients not provided by other pulmonary arterial hypertension therapies.

Know how to make God laugh?
Tell Her your plans ....

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today